Skip to content

Efficacy and safety of a whole grains and beans diet on fasting blood sugar in patients with overweight or obesity and type 2 diabetes mellitus

Efficacy and safety of a whole grains and beans diet on fasting blood sugar in patients with overweight or obesity and type 2 diabetes mellitus

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400090128
Enrollment
Unknown
Registered
2024-09-24
Start date
2024-10-08
Completion date
Unknown
Last updated
2024-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

T2DM

Interventions

a whole grains and beans diet intervention with daily calorie restriction:A whole grains and beans diet intervention for 12 weeks, approximately 70% of their total energy requirements per day. The tar
a whole grains and beans diet intervention with daily calorie restriction:A whole grains and beans diet intervention for 12 weeks, approximately 100% of their total energy requirements per day. The ta
Control group with daily calorie restriction:A control diet intervention for 12 weeks, approximately 70% of their total energy requirements per day. The targeted percentages of energy derived from fat
Control group without calorie restriction:A control diet intervention for 12 weeks, approximately 100% of their total energy requirements per day. The targeted percentages of energy derived from fat,

Sponsors

Peking Union Medical College Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: Voluntarily join and sign an informed consent form; Type 2 diabetes patients diagnosed within 6 years; 25 kg/m2=BMI; 18 years old = age<64 years old; Currently, insulin and GLP-1 drugs are not being used;

Exclusion criteria

Exclusion criteria: Type 1 diabetes, autoimmune diabetes, and other special types of diabetes (cortisolism, growth hormone tumor, glucagon tumor, and some special types of diabetes caused by genetic factors); Acute cardiovascular and cerebrovascular events or myocardial infarction within 12 months; Laboratory examination: Liver function AST and/or ALT = 2.5 × ULN; Renal function Cr>1.2 × ULN; Individuals with severe gastrointestinal diseases, such as active peptic ulcers, intestinal obstruction, etc; There is a change in the normal structure of the gastrointestinal tract Those who have a history of surgery; Hypertensive patients with poor blood pressure control (SBP = 160mmHg and/or DBP = 100mmHg); Individuals with severe hematological disorders; Those who have other endocrine system diseases, such as hyperthyroidism or Cushing's syndrome, in combination; Individuals with stress state or secondary factors of elevated blood glucose levels; Pregnant or lactating women, women who plan to conceive or do not wish to use contraception during the study period; Drug or other drug abusers; Individuals who have lost more than 5kg in weight in the past 3 months; Individuals who have participated in other drug trials within the past 3 months; Individuals with mental illnesses or other conditions who are unable to cooperate; Patients who have undergone metabolic surgery; In other cases, researchers believe that participants are not suitable for inclusion.

Design outcomes

Primary

MeasureTime frame
fasting blood-glucose;

Secondary

MeasureTime frame
Weight and body composition;Cardiovascular risk factors, such as blood pressure, blood lipids, and other indicators;Inflammatory indicators;Sleep;

Countries

China

Contacts

Public ContactKANG JUNREN

Department of Clinical Nutrition, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

kangjunren@pumch.cn+86 158 1039 5852

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026